Allarity Therapeutics

ALLR56

Penny Stock

$1.32arrow_drop_down5.67%-$0.07

Penny Stock

ALLR56

$1.32

arrow_drop_down5.67%-$0.07

Penny Stock

Performance History

Key Stats
Open	$1.40
Prev. Close	$1.41
EPS	-10.98
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$1.86M
PE Ratio	-

	LOW	HIGH
Day Range	1.28	1.48
52 Week Range	1.27	666.00

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-10.98

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

•

About Allarity Therapeutics (ALLR)

Allarity Therapeutics, Inc. (ALLR) is a biotechnology company focused on developing personalized medicine to improve cancer treatment outcomes. The company’s innovative platform, known as the Drug Response Predictor (DRP), uses genomic data to identify patients most likely to respond to specific cancer therapies. By tailoring treatment plans to individual patients, Allarity aims to increase response rates and reduce unnecessary treatment side effects. The DRP analyzes gene expression profiles, clinical data, and drug response data to generate predictive algorithms for various cancer drugs. This enables physicians to select the most effective treatment options for their patients, leading to improved outcomes and potentially saving lives.

Allarity Therapeutics, Inc. is dedicated to advancing cancer treatment through personalized medicine. The company's focus on precision oncology aims to improve patient outcomes by identifying the right therapies for the right patients. By harnessing the power of genomic data, Allarity is able to predict drug response and guide treatment decisions. The Drug Response Predictor (DRP) platform, developed by the company, analyzes multiple factors such as gene expression patterns, clinical data, and previous drug response data to create personalized algorithms. These algorithms help physicians identify the most effective treatment options for individual patients, maximizing the chances of success while minimizing potential side effects. With a commitment to innovation and patient-centric care, Allarity Therapeutics, Inc. is at the forefront of revolutionizing cancer treatment.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. James G. Cullem J.D.
Headquarters: Boston
Employees: 0
Exchange: NASDAQ

add Allarity Therapeutics to watchlist

Keep an eye on Allarity Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Allarity Therapeutics's (ALLR) price per share?

The current price per share for Allarity Therapeutics (ALLR) is $1.32. The stock has seen a price change of -$0.08 recently, indicating a -5.67% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Allarity Therapeutics (ALLR)?

For Allarity Therapeutics (ALLR), the 52-week high is $666, which is 50.35K% from the current price. The 52-week low is $1.27, the current price is 3.86% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Allarity Therapeutics (ALLR) a growth stock?

Allarity Therapeutics (ALLR) has shown an average price growth of -6.65% over the past three years. It has received a score of 84 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Allarity Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Allarity Therapeutics (ALLR) stock price performance year to date (YTD)?

As of the latest data, Allarity Therapeutics (ALLR) has a year-to-date price change of -99.59%. Over the past month, the stock has experienced a price change of -20.96%. Over the last three months, the change has been -73.87%. Over the past six months, the figure is -93.46%.

help

Is Allarity Therapeutics (ALLR) a profitable company?

Allarity Therapeutics (ALLR) has a net income of -$11.9M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$17.93M. Furthermore, the EBITDA is -$16.9M.

help

What is the market capitalization of Allarity Therapeutics (ALLR)?

Allarity Therapeutics (ALLR) has a market capitalization of $1.86M. The average daily trading volume is 1.33, indicating the stock's liquidity and investor engagement.

News

ALLARITY THERAPEUTICS

SECURITIES CLASS ACTION

ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALLR

ALLARITY THERAPEUTICS

CLASS ACTION LAWSUIT

SECURITIES FRAUD

ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

ALLARITY THERAPEUTICS

SECURITIES CLASS ACTION

ALLR FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – ALLR

ALLARITY THERAPEUTICS

SEC INVESTIGATION

FEDERAL SECURITIES CLASS ACTION

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

ALLARITY THERAPEUTICS

SECURITIES CLASS ACTION

מועד אחרון לתביעה נגד ALLER: רוזן, יועץ למשקיעים המדורג ראשון, מעודד את משקיעי Allarity Therapeutics, Inc להבטיח ייעוץ לפני תאריך יעד חשוב של 12 בנובמבר בתביעה ייצוגית בניירות ערך – ALLR

ALLARITY THERAPEUTICS

SECURITIES CLASS ACTION

ALLR 截止日期通知：全球領先的律師事務所 ROSEN 鼓勵 Allarity Therapeutics, Inc. 投資者在證券集體訴訟的重要截止日期 11 月 12 日之前聘請律師 - ALLR

Take Your Investments to a Whole New Level